This event is now closed, information is displayed here for information only.
The 2017 ‘Frontiers of Oncology: Haematology’ meeting will be announced in January 2017
but you can pre-register HERE to be advised when the programme is released

 

A one day meeting held on
Wednesday 28th September 2016
The Royal College of Physicians, London, UK


Chairs

Professor Jonathan Ledermann
Professor Jonathan Ledermann
Professor of Medical Oncology &
Director of the CRUK UCL Trials centre
UCL Cancer Institute
Professor Martin Widschwendter
Professor Martin Widschwendter
Professor in Women’s Cancer &
Head of the Department of Women’s Cancer
University College London

 

SESSION 1: Breast and Ovarian Cancer Screening
08.00 Registration & Coffee
09.00 Welcome / setting the scene: the Chairmen
09.05 The UK Collaborative Trial of Ovarian Cancer Screening – Outcomes (inc. Q&A)
Professor Usha Menon
Professor of Gynaecological Cancer at the UCL Elizabeth Garrett Anderson Institute for Women’s Health and Consultant Gynaecologist, UCLH NHS Trust, London
09.35 The UK Familial Ovarian Cancer Screening Study – the Outcome (inc. Q&A)
Mr Adam Rosenthal
Clinical lead, UK Familial Ovarian Cancer Screening Study, UCL EGA Institute for Women’s Health
 10.05 Keynote Speaker
Harms and benefits of mammography screening
Professor Harry de Koning
Professor of Public Health & Screening Evaluation, Department of Public Health Erasmus MC, Rotterdam, the Netherlands
 10.35 Summary
10.40 Break
11.10 Keynote Speaker
Global surveillance of cancer survival (CONCORD programme)
Professor Michel Coleman
Professor of Epidemiology and Vital Statistics, LSHTM, London, UK
SESSION 2: Risk Prediction and Prevention
11.40 State of the Art: Breast and Cervical Cancer Prevention
Professor Jack Cuzick
Director, Wolfson Institute of Preventive Medicine; Head of the Centre for Cancer Prevention, & John Snow Professor of Epidemiology at Queen Mary, University of London, UK
12.10 Early Detection, Risk Prediction and Prevention of Gynaecological Malignancies and Breast Cancer – Future Directions
Professor Martin Widschwendter
Professor in Women’s Cancer, Head of the Department of Women’s Cancer at University College London; Consultant Gynaecological Oncology Surgeon at University College London Hospital, London, UK
12.40 Summary
12.45 Lunch
SESSION 3: Targeted Treatment
13.45 PARP inhibitors and BRCA genes: a new chapter for personalising therapy
Professor Jonathan Ledermann
Professor of Medical Oncology at UCL Cancer Institute; Director of the Cancer Research UK & UCL Cancer Trials Centre
14.15 Phase1 Showcase – including immunotherapies in Women’s Health
Dr Rebecca Kristeleit
Clinical Senior Lecturer and Consultant Medical Oncologist, UCL Cancer Centre, London, UK
14.45 Targeting Breast Cancer
Dr Rebecca Roylance
Pathway Director for Breast Cancer, London Cancer; UCLPartners Integrated Cancer Programme
15.15 Break
15.45 Using Specialised Radiology for Functional Imaging of Established Cancer
Professor Nandita Desouza
Professor in Translational Imaging, co-director of the Cancer Research UK Clinical Magnetic Resonance Research Group, The Institute of Cancer Research, London, UK
16.15 Summary
SESSION 4: Obesity
16.20 Surgical treatment of obese cancer patients
Mr Tim Mould
Consultant Gynaecologist and Gynaecological Oncologist, UCLH Gynaecological Cancer Centre, London, UK
16.50 Lifestyle Interventions, Obesity & Endometrial Cancer
Dr Rebecca Beeken
Senior Research Psychologist, Health Behaviour Research Centre, Department of Epidemiology and Public Health, UCL, London, UK
17.20 Summary & Close

Costs
The meeting costs will be underwritten by Pharmaceutical Industry sponsors and the event is free of charge for healthcare professionals to attend. Places are strictly limited by room capacity.

 

This meeting is organised by:

New UCL Logo2 800

ATL-new-logo-July-2015-800px

 

and endorsed and supported by:

TLO
TL
Logo RGB
Cochrane_subgroup_Stacked_CMYK


The Frontiers of Oncology 2018 meetings are supported by grants from the Pharmaceutical Industry.
As support agreements are reached, disclosure of the supporters is listed here.